Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Gastroesophageal Reflux Disease (GERD) Segmentation: Document How Swiss General Practitioners (GPs) Allocate Their GERD Patients to the Three GERD Patient Segments

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00688675
First received: May 29, 2008
Last updated: December 6, 2010
Last verified: December 2010
  Purpose
Document how Swiss GPs allocate their GERD patients to the three GERD patient segments (according to King et al.) and how treated GERD patients are affected by their GERD treatment

Condition
GERD

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: GERD Segmentation: Document How Swiss GPs Allocate Their GERD Patients to the Three GERD Patient Segments

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • % patients per GERD patient segment [ Time Frame: single visit ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Symptom load [ Time Frame: single visit ] [ Designated as safety issue: No ]
  • Quality of life [ Time Frame: single visit ] [ Designated as safety issue: No ]

Estimated Enrollment: 2912
Study Start Date: February 2008
Study Completion Date: August 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts
Treated GERD pts
Previously diagnosed GERD patients on treatment in Switzerland

  Eligibility

Ages Eligible for Study:   12 Years and older   (Child, Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Previously diagnosed GERD patients on treatment for at least 2 weeks; in Switzerland
Criteria

Inclusion Criteria:

  • Previously diagnosed GERD patients
  • on treatment for at least 2 weeks

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00688675

Locations
Switzerland
Research Site
Aarau, Switzerland
Sponsors and Collaborators
AstraZeneca
  More Information

Responsible Party: Dr med Madeleine Billeter, AstraZeneca AG, Switzerland
ClinicalTrials.gov Identifier: NCT00688675     History of Changes
Other Study ID Numbers: NIS-GCH-NEX-2007/1 
Study First Received: May 29, 2008
Last Updated: December 6, 2010
Health Authority: Switzerland: Ethikkommission

Keywords provided by AstraZeneca:
GERD
Pharmacoepidemiology

Additional relevant MeSH terms:
Gastroesophageal Reflux
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on September 28, 2016